A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration

PHASE2TerminatedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

July 30, 2020

Primary Completion Date

February 18, 2022

Study Completion Date

March 21, 2022

Conditions
Dry Age-related Macular DegenerationGeographic AtrophyMacular DegenerationRetinal DiseaseRetinal Degeneration
Interventions
DRUG

GEM103

Biological

Trial Locations (29)

23454

Gemini Clinical Trial Site, Virginia Beach

28210

Gemini Clinical Trial Site, Charlotte

28803

Gemini Clinical Trial Site, Asheville

30060

Gemini Clinical Trial Site, Marietta

30909

Gemini Clinical Trial Site, Augusta

32308

Gemini Clinical Trial Site, Tallahassee

33410

Gemini Clinical Trial Site, Palm Beach Gardens

33711

Gemini Clinical Trial Site, St. Petersburg

33880

Gemini Clinical Trial Site, Winter Haven

46290

Gemini Clinical Trial Site, Indianapolis

57701

Gemini Clinical Trial Site, Rapid City

60304

Gemini Clinical Trial Site, Oak Park

63017

Gemini Clinical Trial Site, Chesterfield

63144

Gemini Clinical Trial Site, St Louis

75231

Gemini Clinical Trial Site, Dallas

77384

Gemini Clinical Trial Site, The Woodlands

79606

Gemini Clinical Trial Site, Abilene

80401

Gemini Clinical Trial Site, Golden

85020

Gemini Clinical Trial Site, Phoenix

89502

Gemini Clinical Trial Site, Reno

90211

Gemini Clinical Trial Site, Beverly Hills

92064

Gemini Clinical Trial Site, Poway

93036

Gemini Clinical Trial Site, Oxnard

93103

Gemini Clinical Trial Site, Santa Barbara

93309

Gemini Clinical Trial Site, Bakersfield

93454

Gemini Clinical Trial Site, Santa Maria

97401

Gemini Clinical Trial Site, Eugene

06320

Gemini Clinical Trial Site, New London

07003

Gemini Clinical Trial Site, Bloomfield

Sponsors
All Listed Sponsors
lead

Gemini Therapeutics, Inc.

INDUSTRY